Results 281 to 290 of about 231,281 (308)

Disparities in deworming coverage between children with and without disabilities: insights from the DeWorm3 trial in India. [PDF]

BMJ Glob Health
Chen S, Ramesh RM, Aruldas K, Kaliappan SP, Chandy BR, Koshy B, Jasper S, Halliday KE, Walson JL, Oswald W, Ajjampur SSR, Kuper H.   +11 more
europepmc   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. [PDF]

Clin Infect Dis
Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, Boyle A, Senneker T, George J, Lund C, Belperio P, Crew P, Eschenauer G, Scarsi KK, Khoo SH, Pau A, Marzolini C, LiON-PK collaboration .   +17 more
europepmc   +1 more source

A Case of Clinical and Viral Rebound Following Completion of a Five-Day Course of Ensitrelvir for COVID-19. [PDF]

Cureus
Kasamatsu Y, Shiraisi S, Uji M, Kobayashi M, Goto T, Hiura Y.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Drugs for the Treatment of COVID-19

2021
Currently, there are no drugs or other therapeutic agents approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19. Current standard of care includes prevention of infection and control measures and supportive care, including supplemental oxygen and, when required, mechanical ventilatory support.
Sagheer Ahmed, Halimur Rehman, Rehan Salar, May Nasser Bin-Jumah, M. Tauseef Sultan, Marius Moga   +5 more
openaire   +1 more source

Phytotherapic Drugs for COVID-19 Treatment: A Scoping Review

Current Pharmaceutical Design, 2021
Background: The rapid eruption of Coronavirus at the end of 2019 has caused global health crisis and significant loss to the economy and social well-being. This created a massive shortage of advanced health facilities with inadequate medicinal supply, further deteriorating human health conditions.
Meenakshi, Singh, Darshini, Trivedi, Reecha, Mohapatra, Trisha, Bagchi, Chandrasai P, Durthi, Chandrasekhar, Kuppam   +5 more
openaire   +2 more sources

COVID-19 drug discovery and treatment options

Nature Reviews Microbiology
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and mortality, and serious social and economic disruptions worldwide. Unvaccinated or incompletely vaccinated older individuals with underlying diseases are especially prone to severe disease.
Jasper Fuk-Woo Chan, Shuofeng Yuan, Hin Chu, Siddharth Sridhar, Kwok-Yung Yuen   +4 more
openaire   +2 more sources

A review on drug repurposing applicable to COVID-19

Briefings in Bioinformatics, 2021
Serena Dotolo, Anna Marabotti, Angelo Facchiano   +2 more
exaly  

Identification of Drug Interaction Adverse Events in Patients With COVID-19

JAMA Network Open, 2022
Valeria Conti, Carmine Sellitto, Valentina Manzo   +2 more
exaly